Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer?

Radiopharm Theranostics Limited (ASX: RAD | Nasdaq: RADX) has cleared a key clinical milestone in its effort to bring a novel radiopharmaceutical therapy to market for patients with advanced PD-L1 positive cancers. The Australian biopharmaceutical firm, listed on both the Australian Securities Exchange (ASX) and the Nasdaq Capital Market, confirmed on November 12, 2025, that it has commenced enrollment for the third cohort in its Phase 1 dose escalation trial of 177Lu-RAD204. This progression follows the greenlight from the trial’s Data Safety Monitoring Committee, which approved a higher dose of 90 millicuries of Lutetium-177 following favorable safety data and confirmed tumor uptake in the first two cohorts.

What is the significance of escalating to a 90mCi dose in Radiopharm Theranostics’ Phase 1 trial?

The trial, conducted under an open-label, Phase 0/1 protocol, is formally titled “Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumors.” It is designed to evaluate safety, biodistribution, radiation dosimetry, and preliminary antitumor activity in patients with a wide range of PD-L1 expressing malignancies. These include non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, cutaneous melanoma, head and neck squamous cell carcinoma, and endometrial cancer.

This Phase 1 dose escalation trial is considered a foundational step in validating Radiopharm Theranostics’ approach to targeting PD-L1 through a radiopharmaceutical pathway. The use of Lutetium-177 combined with a single-domain monoclonal antibody enables high tumor specificity and localized cytotoxicity while maintaining a favorable systemic safety profile. Such a combination could potentially overcome resistance mechanisms associated with immune checkpoint inhibitors or standard chemotherapy regimens, particularly in tumors with poor response rates.

How is Radiopharm Theranostics positioning 177Lu-RAD204 in a crowded PD-L1 oncology space?

Chief Executive Officer Riccardo Canevari stated that the successful completion of the second cohort’s enrollment reflects the company’s disciplined clinical execution. He emphasized that the study’s basket design enables Radiopharm Theranostics to address multiple cancer types simultaneously, accelerating the understanding of 177Lu-RAD204’s potential across different PD-L1 positive tumor microenvironments. The ability to proceed with the higher 90mCi dose represents a pivotal inflection point in the trial’s development, further validating the tolerability observed in the earlier dosing groups.

The target of this radiotherapeutic agent, PD-L1, is a well-established immune checkpoint protein known for its role in tumor immune evasion. It is overexpressed in numerous advanced solid tumors, making it a high-value target for next-generation oncology therapeutics. Unlike systemic immunotherapy that relies on broad immune activation, radiopharmaceutical approaches like 177Lu-RAD204 deliver radiation directly to PD-L1 expressing tumor cells, minimizing off-target toxicity and potentially offering therapeutic value even in patients previously refractory to immunotherapies.

What makes RAD204’s nanobody format and theranostic approach a competitive differentiator?

The compound itself, RAD204, is a single-domain antibody derived from camelid antibodies. These nanobodies are smaller and more penetrative than conventional full-length antibodies, which can improve tumor access and reduce systemic retention. In a prior imaging-focused Phase 1 study involving 16 patients with non-small cell lung cancer, the company utilized the diagnostic companion agent 99mTc-RAD204 to demonstrate safety and acceptable radiation dosimetry. Those results provided the preclinical and clinical rationale for proceeding into therapeutic dosing with 177Lu-RAD204.

While the current trial is still at an early stage, the decision to escalate dosing to 90 millicuries suggests that the agent is well tolerated and that preliminary biodistribution data are supportive of further exploration. Radiopharm Theranostics is pursuing a modular development approach in which multiple tumor types are evaluated under a single study protocol. This basket trial strategy not only expedites data collection across various cancers but also provides insights into tumor-specific biodistribution, enabling future indication prioritization.

How does 177Lu-RAD204 align with Radiopharm’s broader oncology pipeline and strategy?

At the corporate level, Radiopharm Theranostics is positioning itself as a global leader in radiopharmaceuticals for oncology. The company’s broader pipeline includes five active clinical trials, comprising one Phase 2 and four Phase 1 programs. These trials leverage a diverse array of platforms including peptides, small molecules, and antibodies, with a therapeutic focus on cancers of the lung, brain, and breast. The emphasis on both diagnostic and therapeutic modalities allows Radiopharm Theranostics to offer a theranostic approach, which has gained traction among oncologists seeking more personalized and targeted treatment solutions.

Radiopharm Theranostics is currently traded on the Australian Securities Exchange under the ticker RAD and on the Nasdaq under RADX. The company reported a market capitalization of approximately 66.74 million Australian dollars as of the market close on November 12, 2025. Its share price stood at 0.024 Australian dollars, unchanged from the previous session, with a trading volume exceeding 14.5 million shares. Over the past year, the stock has experienced a decline of 11.11 percent, reflecting broader volatility in the small-cap biotech space. Despite the negative return, the company ranks 90th out of 235 in the healthcare sector on the Australian Securities Exchange and 1,176th among 2,305 listed companies.

What is the investor outlook as Radiopharm Theranostics continues dose escalation in PD-L1 cancers?

Investor sentiment remains cautious but watchful. While the company has not yet reported revenue and carries a price-to-earnings ratio of zero, institutional observers are closely monitoring the progression of its PD-L1 program as a potential clinical value driver. The initiation of dosing in the third cohort is likely to be interpreted as a signal that the therapy is advancing safely and may soon yield more definitive efficacy readouts. Investors may now look for updates around response markers such as progression-free survival, tumor shrinkage, and biomarker correlation studies as the trial enters a more data-rich phase.

The strategic relevance of this development lies not only in the clinical performance of 177Lu-RAD204 but also in its implications for the broader field of radiopharmaceuticals. As big pharma begins to show interest in radiotherapeutics with recent acquisitions and licensing deals, small-cap innovators like Radiopharm Theranostics could find themselves well positioned for potential partnerships or collaborations if early clinical signals prove positive. The PD-L1 space, although crowded with monoclonal antibody-based immunotherapies, still presents unmet needs in patient subsets that are non-responsive or relapse-prone. By combining PD-L1 targeting with radiotherapy, Radiopharm Theranostics aims to offer a differentiated treatment paradigm.

What should stakeholders expect next as the third cohort advances and data maturity increases?

Over the coming months, the company is expected to continue patient enrollment and dosing in the third cohort while collecting longitudinal safety and biodistribution data. The next set of updates may provide insight into tumor response, durability of targeting, and potential expansion paths into Phase 2. As Radiopharm Theranostics navigates this critical stage, success in maintaining safety at the 90mCi dose could serve as a launchpad for higher clinical interest, strategic funding, or eventual regulatory engagement.

The oncology community will also observe how Radiopharm Theranostics integrates its theranostic approach into real-world clinical pathways. With multiple solid tumors under evaluation and a growing interest in personalized radiotherapies, the company’s efforts could contribute to reshaping how targeted radiation is used in cancer treatment beyond traditional nuclear medicine.

What are the key takeaways from Radiopharm Theranostics’ third cohort update for 177Lu-RAD204?

• Radiopharm Theranostics Limited has advanced to the third cohort of its Phase 1 trial for 177Lu-RAD204, a PD-L1 targeting radiopharmaceutical for solid tumors.
• The company received Data Safety Monitoring Committee approval to escalate the dose to 90 millicuries, following favorable safety data and confirmed tumor uptake in the first two cohorts.
• The open-label basket trial is evaluating multiple PD-L1 positive cancers, including non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, melanoma, head and neck squamous cell carcinoma, and endometrial cancer.
• RAD204 is a single-domain antibody conjugated with Lutetium-177, designed to deliver targeted radiotherapy with improved tumor penetration and minimal off-target toxicity.
• Prior imaging studies using 99mTc-RAD204 in 16 non-small cell lung cancer patients confirmed acceptable safety and radiation dosimetry, supporting the progression to therapeutic use.
• The company’s broader pipeline includes five active clinical trials, with a theranostic approach spanning peptides, antibodies, and small molecules for solid tumors.
• Radiopharm Theranostics is listed on both the Australian Securities Exchange (ASX: RAD) and Nasdaq (RADX), with a current market capitalization of approximately AUD 66.74 million.
• The share price closed flat at AUD 0.024 on November 12, 2025, with a 52-week range of AUD 0.019 to AUD 0.042 and a year-to-date decline of 11.11 percent.
• Analysts tracking the stock are awaiting early efficacy data and longitudinal tumor response signals, which could de-risk the asset and improve sentiment.
• The oncology sector is closely watching Radiopharm’s progress, particularly as radiopharmaceutical innovation gains traction as a precision therapy alternative.